ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0258

Health-Related Quality of Life in Roxadustat-Treated Patients with Anemia and Non-Dialysis-Dependent CKD

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Coyne, Daniel W., Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States
  • Manllo-Karim, Roberto, South Texas Kidney Specialists, P.A., McAllen, Texas, United States
  • Pergola, Pablo E., Renal Associates PA, San Antonio, Texas, United States
  • Pollock, Carol A., The University of Sydney, Sydney, New South Wales, Australia
  • Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Lee, Tyson T., FibroGen Inc, San Francisco, California, United States
  • Hardy, Elise, AstraZeneca, Gaithersburg, Maryland, United States
  • Yu, Kin-Hung Peony, FibroGen Inc, San Francisco, California, United States
Background

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and improves iron metabolism. Anemia in CKD impacts health-related quality of life (HRQL) by reducing physical capacity and energy levels. Studies have demonstrated a direct relationship between HRQL scores and hemoglobin (Hb) levels in non–dialysis-dependent (NDD) and dialysis-dependent patients with CKD. We assessed the impact of roxadustat on HRQL in patients with NDD-CKD.

Methods

Pooled data from three pivotal, phase 3, randomized, double-blind, placebo-controlled studies of roxadustat for the treatment of anemia in patients with NDD-CKD were assessed. Patients with data up to the time of dialysis treatment and who had pretreatment and ≥1 post-treatment HRQL measurement were included. Mean changes from baseline to Week 12 in HRQL scores were compared between the treatment groups.

Results

Least-squares mean treatment differences favored the roxadustat group at Week 12 (all p-values <0.05) in the majority of measures analyzed (Table). Between-group differences were larger in subgroups with lower (ie, worse) baseline scores.

Conclusion

Roxadustat demonstrated improvement in most HRQL measures vs. placebo in patients with NDD-CKD.

Funding

  • Commercial Support